Halozyme Therapeutics, Inc.
HALO
$47.90
-$2.33-4.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.81% | 0.00% | 46.94% | 21.38% | -10.03% |
| Total Depreciation and Amortization | 0.17% | 0.27% | 0.14% | 0.62% | -2.35% |
| Total Amortization of Deferred Charges | 0.11% | 0.16% | 0.33% | 0.27% | 0.11% |
| Total Other Non-Cash Items | 203.01% | -161.10% | -55.39% | 151.25% | -56.12% |
| Change in Net Operating Assets | -70.55% | 147.03% | 34.43% | -481.64% | 182.60% |
| Cash from Operations | -13.59% | 54.68% | 106.79% | -56.89% | 26.45% |
| Capital Expenditure | 68.87% | -101.19% | 41.25% | 27.17% | -36.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -375.03% | 119.60% | -320.62% | 50.14% | -1,289.57% |
| Cash from Investing | -406.72% | 117.60% | -298.40% | 49.16% | -897.24% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -80.69% | 95.75% | -- | -- |
| Repurchase of Common Stock | 98.67% | -- | -- | -- | 99.81% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 98.65% | -1,427.60% | 95.75% | 2,039.06% | 99.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 257.22% | -14.67% | -244.36% | -49.77% | 129.68% |